Safety and tolerability of one-year intramuscular testosterone regime to induce puberty in older men with CHH. Issue 1 (January 2018)

• Record Type: Journal Article
• Authors: Pazderska, Agnieszka; Mamoojee, Yaasir; Artham, Satish; Miller, Margaret; Ball, Stephen G; Cheetham, Tim; Quinton, Richard
• Is Part Of: Endocrine connections. Volume 7:Issue 1(2018)
• Page Start: 133
• Page End: 138
• Publication Date: 2018-01
• Subjects: absent puberty -- intramuscular testosterone -- congenital hypogonadotrophic hypogonadism -- older men -- Kallmann's syndrome; Endocrinology -- Periodicals; 616.4005
• DOI: 10.1530/EC-17-0241
• Languages: English
• ISSNs: 2049-3614

Abstract

Abstract : We present herein our 20-year experience of pubertal induction in apubertal older (median age 56 years; range 38.4–69.5) men with congenital hypogonadotrophic hypogonadism ( n = 7) using a simple fixed-dose and fixed-interval intramuscular testosterone that we originally pioneered in relation to achieving virilisation of natal female transgender men. This regime was effective and well tolerated, resulting in complete virilisation by around 1 year after treatment initiation. No physical or psychological adverse effects were encountered in this group of potentially vulnerable individuals. There were no abnormal excursions of laboratory parameters and extended follow-up beyond the first year of treatment revealed remarkable improvements in bone density. We highlight advantages to both patients and physicians of this regime in testosterone-naïve older men with congenital hypogonadism and discourage the over-rigid application to such patients of treatment algorithms derived from paediatric practice in relation to the evaluation and management in younger teenagers with delayed puberty of uncertain cause.